|
Office Locations:
|
12/F International Commerce Centre
1 Austin Road West, Unit 01
Kowloon,
Hong Kong
| |
|
|
|
|
Life Sciences & Healthcare
Medical Device
|
|
|
OrbiMed is the world's largest healthcare-dedicated investment firm managing over $13 billion across public and private company investments worldwide. OrbiMed's investment advisory business was founded in 1989 with a vision to invest across the spectrum of healthcare companies from private start-ups to large multinational companies. OrbiMed manages the Caduceus Private Investments series of venture capital funds and a family of public equity investment funds. OrbiMed seeks to be the capital provider of choice for life sciences companies pursuing growth and new opportunities. As a result of OrbiMed's growing capabilities in private equity, the firm launched a dedicated venture capital fund, Caduceus Private Investments, in 2000. Caduceus Private Investments II followed in 2003 and Caduceus Private Investments III was launched in 2006 with committed capital of over $500 million. In 2011 OrbiMed launched a Royalty Opportunities fund, focused on investing in healthcare royalty streams. Today, OrbiMed has a singular focus on seeking successful investments on a worldwide basis across the entire spectrum of private and publicly-traded life sciences companies. For privately-held companies, OrbiMed typically invests between $5 million and $40 million and the firm prefers mid-stage companies focused on drug development, drug discovery, and medical devices. The firm announced in Fall of 2013 the close of OrbiMed Private Investments V, LP, with just over $735 million in commitments, including approximately $36 million from the General Partner. In December 2015, the firm announced OrbiMed Private Investments VI, LP, with $950 million in limited partner commitments.
|
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
COMPANY STAGE | REVENUE |
Venture Capital | |
Seed Stage (includes "pre-seed," or concept stage) | No Revenue |
Early Stage | Minimal Revenue |
Growth Stage (also called Mid-stage) | $2M-$7M |
Expansion Stage (also called Late-stage) | $7M and greater |
Private Equity | |
Lower Middle Market | $10M-$249M |
Middle Market | $250M-$499M |
Upper Middle Market | $500M-$1B |
Large Cap | >$1B |
|
|
|
|